Ubenimex in Adult Patients With Lymphedema of The Lower Limb (ULTRA)

Status Completed

Clinical Trial Summary

This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema.

Clinical Trial Description

Leukotriene B4 (LTB4) inhibits lymphangiogenesis in the mouse tail model of lymphedema and is elevated in tissue in patients with lymphedema. Ubenimex is an inhibitor of leukotriene A4 hydrolase (LTA4H), the biosynthetic enzyme for LTB4. This proof-of-concept study is designed as a randomized, double-blind, placebo-controlled study comparing ubenimex at 150 mg, 3 times daily (total daily dose of 450 mg) with placebo for 6 months treatment period in patients with leg lymphedema. The primary objectives for the study are: - To evaluate the efficacy of ubenimex in patients with leg lymphedema - To evaluate the safety and tolerability of ubenimex in patients with leg lymphedema ;

Study Design

Related Conditions & MeSH terms

Lymphedema

Clinical Trial Details

NCT number	NCT02700529
Study type	Interventional
Source	Eiger BioPharmaceuticals
Contact
Status	Completed
Phase	Phase 2
Start date	June 2016
Completion date	February 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05507346` - A Clinical Study to Evaluate the Effectiveness of a Novel Portable Non-Pneumatic Active Compression Device vs. an Advanced Pneumatic Compression Device for Treating Lower Extremity Lymphedema	N/A
Completed	`NCT06067880` - Surgical Intervention and Lymphatic Diseases.
Active, not recruiting	`NCT04797390` - A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema	N/A
Completed	`NCT02676752` - Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and Fibrosis
Completed	`NCT02506530` - Treatment Pathway of Patients Suffering From a Breast Cancer Related Lymphoedema	N/A
Completed	`NCT06323200` - Lymphedema Duration on Lymphatic Vessel Quality and Outcomes After LVA
Terminated	`NCT02020837` - A Pilot Study Assessing the Effect of Lymphaticovenous Micro-Anastomosis in the Treatment of Postmastectomy Lymphedema	Early Phase 1
Completed	`NCT02253186` - Clinical Study to Assess Safety and Efficacy of a New Armsleeve in the Management of Arm Lymphoedema	N/A
Recruiting	`NCT01318785` - Therapeutical Assessment of Compression Armsleeves for Lymphatic Indications	Phase 2
Enrolling by invitation	`NCT02375165` - Biomarkers for the Detection of Lymphatic Insufficiency
Completed	`NCT00852930` - Low Level Laser Treatment and Breast Cancer Related Lymphedema	Phase 4
Completed	`NCT01112189` - Use of Stem Cells in Lymphedema Post Mastectomy	Phase 1/Phase 2
Completed	`NCT02308488` - Study of Prone Accelerated Breast And Nodal IMRT	N/A
Completed	`NCT00743314` - Single-Photon Emission Computed Tomography, Computed Tomography Lymphoscintigraphy, and Intensity-Modulated Radiation Therapy in Treating Patients Who Have Undergone Surgery for Stage I or Stage II Breast Cancer	Early Phase 1
Recruiting	`NCT06237907` - Pyroptosis and Ferroptosis in the Pathophysiology of Lymphedema
Terminated	`NCT01580800` - National Breast Cancer and Lymphedema Registry
Suspended	`NCT05366699` - LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy	N/A
Completed	`NCT06249360` - Lymphatic System Reflux After Lymphatic Operation
Completed	`NCT06220903` - The Effect of Complex Decongestive Therapy in Patients With Lymphedema	N/A
Terminated	`NCT02923037` - Hatha Yoga in Breast Cancer Survivors	N/A